Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 173Advanced Solid Tumor 150Solid Tumor 129Mesothelioma 88Mesothelioma, Malignant 81Solid Tumors 79Hematopoietic and Lymphatic System Neoplasm 47Solid Tumor, Adult 35Carcinoma, Non-Small-Cell Lung 32Retinoblastoma 29Ovarian Neoplasms 26Melanoma 24Colorectal Neoplasms 22Pancreatic Neoplasms 21Stomach Neoplasms 20Sarcoma 20Lung Neoplasms 19Carcinoma, Renal Cell 18Uterine Cervical Neoplasms 16Esophageal Neoplasms 16Neoplasms 15Malignant Solid Neoplasm 15Neoplasm Metastasis 14Hematopoietic and Lymphoid System Neoplasm 14Advanced or Metastatic Solid Tumors 14Triple Negative Breast Neoplasms 13Solid Tumor Malignancies 13Small Cell Lung Carcinoma 13Advanced Malignant Solid Tumor 13Urinary Bladder Neoplasms 12

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatic Impairment × Other solid neoplasm × 1 year × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡